他汀治疗强度与动脉粥样硬化性心血管病患者死亡率的关联
随访平均492天发现,他汀强度与全因死亡率呈梯度关联,高强度组较小但显著优于中强度组。
要点
- 他汀治疗强度与ASCVD患者全因死亡率呈梯度负相关,高强度组死亡率最低。
- 倾向评分校正后,高强度较中强度他汀死亡的HR为0.91(95%CI 0.88-0.93)。
- 高强度他汀最大剂量者死亡风险低于亚最大剂量者(HR 0.90,95%CI 0.87-0.94)。
核心结论
- 在退伍军人事务医疗系统的ASCVD患者中,他汀治疗强度与全因死亡率呈梯度关联。
- 与中强度他汀相比,高强度他汀与小幅但显著的生存获益相关,在老年患者中亦如此。
- 高强度他汀使用最大剂量者较亚最大剂量者进一步获得生存获益。
研究设计与样本
- 回顾性队列分析,纳入2013年4月1日至2014年4月1日退伍军人事务医疗系统中21至84岁的ASCVD患者。
- 入选者需在既往2年内至少2个不同日期有1个或多个ASCVD的ICD-9编码。
- 他汀强度按2013年ACC/AHA指南定义,用药定义为既往6个月内已配药。
- 排除既往5年内使用更高他汀剂量的患者。
主要发现
- 倾向评分校正后,高强度vs中强度他汀的死亡HR为0.91(95%CI 0.88-0.93)。
- 事件队列中高强度vs中强度他汀的HR为0.93(95%CI 0.85-1.01)。
- 76至84岁患者中HR为0.91(95%CI 0.87-0.95),最大剂量高强度他汀者HR为0.90(95%CI 0.87-0.94)。
关键数值与推荐
- 高强度他汀的定义依据2013年ACC/AHA指南。
- 用药状态依据既往6个月内已配药判定。
- 主要结局为经倾向评分校正的全因死亡。
临床怎么用
- 对已确诊ASCVD患者应评估他汀治疗强度,并优先使用高强度他汀以降低死亡风险。
- 在可耐受前提下,高强度他汀采用最大剂量可能带来进一步生存获益。
- 老年ASCVD患者(76至84岁)高强度他汀仍与生存获益相关,不应仅因年龄降级治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: High-intensity statin therapy is recommended for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD). Nevertheless, statin therapy in general, and high-intensity statin therapy in particular, is underused in patients with established ASCVD. OBJECTIVE: To determine the association between all-cause mortality and intensity of statin therapy in the Veterans Affairs health care system. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort analysis was conducted of patients aged 21 to 84 years with ASCVD treated in the Veterans Affairs health care system from April 1, 2013, to April 1, 2014. Patients who were included had 1 or more International Classification of Diseases, Ninth Revision codes for ASCVD on 2 or more different dates in the prior 2 years. EXPOSURES: Intensity of statin therapy was defined by the 2013 American College of Cardiology/American Heart Association guidelines, and use was defined as a filled prescription in the prior 6 months. Patients were excluded if they were taking a higher statin dose in the prior 5 years. MAIN OUTCOMES AND MEASURES: The primary outcome was death from all causes adjusted for the propensity to receive high-intensity statins. RESULTS: The study sample included 509 766 eligible adults with ASCVD at baseline (mean [SD] age, 68.5 [8.8] years; 499 598 men and 10 168 women), including 150 928 (29.6%) receiving high-intensity statin therapy, 232 293 (45.6%) receiving moderate-intensity statin therapy, 33 920 (6.7%) receiving low-intensity statin therapy, and 92 625 (18.2%) receiving no statins. During a mean follow-up of 492 days, there was a graded association between intensity of statin therapy and mortality, with 1-year mortality rates of 4.0% (5103 of 126 139) for those receiving high-intensity statin therapy, 4.8% (9703 of 200 709) for those receiving moderate-intensity statin therapy, 5.7% (1632 of 28 765) for those receiving low-intensity statin therapy, and 6.6% (4868 of 73 728) for those receiving no statin (P < .001). After adjusting for the propensity to receive high-intensity statins, the hazard ratio for mortality was 0.91 (95% CI, 0.88-0.93) for those receiving high- vs moderate-intensity statins. The magnitude of benefit of high- vs moderate-intensity statins was similar, for an incident cohort hazard ratio of 0.93 (95% CI, 0.85-1.01). For patients aged 76 to 84 years, the hazard ratio was 0.91 (95% CI, 0.87-0.95). Patients treated with maximal doses of high-intensity statins had lower mortality (hazard ratio, 0.90; 95% CI, 0.87-0.94) compared with those receiving submaximal doses. CONCLUSIONS AND RELEVANCE: We found a graded association between intensity of statin therapy and mortality in a national sample of patients with ASCVD. High-intensity statins were associated with a small but significant survival advantage compared with moderate-intensity statins, even among older adults. Maximal doses of high-intensity statins were associated with a further survival benefit.
引用
- Rodriguez F, Maron DJ, Knowles JW, et al. Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017. PMID: 27829091. doi:10.1001/jamacardio.2016.4052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。